Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipids and progressive renal failure

W F Keane1

  • 1Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA.

Wiener Klinische Wochenschrift
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).

Journal of the renin-angiotensin-aldosterone system : JRAAS·2002
Same author

Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure.

Kidney international·2001
Same author

Metabolic pathogenesis of cardiorenal disease.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2001
Same author

The urgent call of albuminuria/proteinuria. Heeding its significance in early detection of kidney disease.

Postgraduate medicine·2001
Same author

[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].

Ugeskrift for laeger·2001
Same author

Proteinuria and cardiovascular disease.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2001
Same journal

[Vaccination of immunocompromised individuals: Expert opinion - update 2026].

Wiener klinische Wochenschrift·2026
Same journal

Systematic review of clinical evidence for Kneipp medicine.

Wiener klinische Wochenschrift·2026
Same journal

Pelvic resections in primary sarcomas : Surgical outcomes and survival analysis of 75 patients.

Wiener klinische Wochenschrift·2026
Same journal

Jungmediziner*innen am Start: 11. Workshop für den medizinischen Nachwuchs.

Wiener klinische Wochenschrift·2026
Same journal

Stellungnahme der ÖGP zur geplanten Gesetzesnovelle zum Nichtraucherschutzgesetz.

Wiener klinische Wochenschrift·2026
Same journal

MUW researcher of the month: Dr. Moritz Schaefer.

Wiener klinische Wochenschrift·2026
See all related articles

Statins, or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, show promise in protecting kidneys from progressive injury. These drugs may offer benefits beyond lipid reduction by influencing mesangial cell biology.

Area of Science:

  • Nephrology
  • Biochemistry
  • Pharmacology

Background:

  • Lipids play a role in progressive renal injury.
  • 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have shown benefits in renal failure models.
  • Emerging data suggests HMG-CoA reductase inhibitors may offer glomerular protection independent of lipid reduction.

Purpose of the Study:

  • To investigate the potential of HMG-CoA reductase inhibitors in modifying mesangial cell biology.
  • To explore the non-lipid-lowering effects of HMG-CoA reductase inhibitors on renal protection.
  • To assess the clinical relevance of HMG-CoA reductase inhibitors in slowing renal disease progression.

Main Methods:

  • In vitro studies on mesangial cell proliferation and chemokine production.

Related Experiment Videos

  • Analysis of nonsterol isoprenoid pathways and protein isoprenylation.
  • Review of clinical studies on lipid abnormalities and renal disease progression.

    • Main Results:

    • HMG-CoA reductase inhibition reduced mesangial cell proliferation and chemokine production.
    • Effects linked to reduced nonsterol isoprenoid synthesis, impacting protein isoprenylation and cell signaling.
    • Clinical studies indicate HMG-CoA reductase inhibitors may slow renal disease progression, even in diabetic patients.

    Conclusions:

    • HMG-CoA reductase inhibitors possess the potential to modify mesangial cell biology independently of their lipid-lowering effects.
    • These agents may offer a therapeutic strategy for progressive renal diseases, including those associated with diabetes.
    • Further research into the non-lipid-lowering mechanisms of HMG-CoA reductase inhibitors is warranted for renal protection and reducing chronic vascular rejection.